Moxetumomab Pasudotox
Lumoxiti (moxetumomab pasudotox) is a CD22-directed cytotoxin used to treat adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including a purine nucleoside analog. It works by binding to CD22 on the surface of abnormal B cells, delivering a toxin that inhibits protein synthesis and causes cell death.
Lumoxiti is a targeted immunotherapy for relapsed or refractory hairy cell leukemia that delivers a bacterial toxin directly to CD22-expressing B cells.
Key facts at a glance
- RxNorm
- 2099310
- Generic
- Lumoxiti
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog (such as cladribine or pentostatin).
Lumoxiti is a recombinant immunotoxin consisting of an anti-CD22 antibody fused to a truncated Pseudomonas exotoxin. It binds specifically to CD22 on the surface of B cells, is internalized, and the toxin component inhibits protein synthesis by ADP-ribosylating elongation factor 2, leading to cell death.
Lumoxiti carries a Boxed Warning for capillary leak syndrome (CLS) and hemolytic uremic syndrome (HUS), which can be fatal. It is available only through a restricted program called LUMOXITI REMS. Patients should be monitored for signs of CLS and HUS, including edema, hypotension, and decreased hemoglobin with schistocytes. Common side effects include infusion-related reactions, edema, nausea, fatigue, and pyrexia.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy